Revolution Medicines Announces Zoldonrasib Showed Manageable Safety, Tolerability Profile In Two Phase 1/2 Clinical Studies; Objective Response Rate Stood At 82%, Disease Control Rate Was 96%

Loading news article.

Revolution Medicines Announces Zoldonrasib Showed Manageable Safety, Tolerability Profile In Two Phase 1/2 Clinical Studies; Objective Response Rate Stood At 82%, Disease Control Rate Was 96% | WAPE

Revolution Medicines Announces Zoldonrasib Showed Manageable Safety, Tolerability Profile In Two Phase 1/2 Clinical Studies; Objective Response Rate Stood At 82%, Disease Control Rate Was 96%

Article summary

Related companies

Comments —